Skip to main content
SpringerLink
Log in

Serotonergic compounds: clinical data

  • Chapter
Drugs for Relapse Prevention of Alcoholism

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Myers RD, Veale WL (1968) Alcohol preference in the rat: reduction following depletion of brain serotonin. Science 160: 1469–1471

    PubMed  CAS  Google Scholar 

  2. Nachman M, Lester D, Le Magnen J (1970) Alcohol aversion in the rat: behavioral assessment of noxious drug effects. Science 168: 1244–1246

    PubMed  CAS  Google Scholar 

  3. Daoust M, Chretien P, Moore N, Saligaut C, Lhuintre JP, Boismare F (1985) Isolation and striatal (3H) serotonin uptake: role in the voluntary intake of ethanol by rats. Pharmacol Biochem Behav 22: 205–208

    Article  PubMed  CAS  Google Scholar 

  4. Geller I (1973) Effects of para-chlorophenylalanine and 5-hydroxytryptophan on alcohol intake in the rat. Pharmacol Biochem Behav 1: 361–365

    Article  PubMed  CAS  Google Scholar 

  5. Gill K, Amit Z, Koe BK (1988) Treatment with sertraline, a new serotonin uptake inhibitor, reduces voluntary ethanol consumption in rats. Alcohol 5: 349–354

    PubMed  CAS  Google Scholar 

  6. Gill K, Filion Y, Amit Z (1988) A further examination of the effects of sertraline on voluntary ethanol consumption. Alcohol 5: 355–358

    PubMed  CAS  Google Scholar 

  7. Zabik JE, Binkerd K, Roache JD (1985) Serotonin and ethanol aversion in the rat. In: CA Naranjo, EM Sellers (eds): Research advances in new psychopharmacological treatments for alcoholism: proceedings of the symposium, Toronto, 4–5 October 1984. Excerpta Medica, Amsterdam, 87–105

    Google Scholar 

  8. Blundell JE, Latham CJ (1982) Behavioural pharmacology of feeding. In: T Silverstone (ed.): Drugs and appetite. Academic Press, London, 41–80

    Google Scholar 

  9. Blundell JE (1984) Serotonin and appetite. Neuropharmacology 23: 1537–1551

    Article  PubMed  CAS  Google Scholar 

  10. Gill K, Amit Z (1989) Serotonin uptake blockers and voluntary alcohol consumption. A review of recent studies. Recent Dev Alcohol 7: 225–248

    PubMed  CAS  Google Scholar 

  11. Haraguchi M, Samson HH, Tolliver GA (1990) Reduction in oral ethanol self-administration in the rat by the 5-HT uptake blocker fluoxetine. Pharmacol Biochem Behav 35: 259–262

    Article  PubMed  CAS  Google Scholar 

  12. Murphy JM, Waller MB, Gatto GJ, McBride WJ, Lumeng L, Li TK (1988) Effects of fluoxetine on the intragastric self-administration of ethanol in the alcohol preferring P line of rats. Alcohol 5: 283–286

    Article  PubMed  CAS  Google Scholar 

  13. Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sanchez-Craig M, Sykora K (1984) Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther 35: 374–381

    Article  PubMed  CAS  Google Scholar 

  14. Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Kadlec K, Sykora K (1987) The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 41: 266–274

    Article  PubMed  CAS  Google Scholar 

  15. Naranjo CA, Sellers EM (1989)Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers. Recent Dev Alcohol 7: 255–266

    PubMed  CAS  Google Scholar 

  16. Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM (1990) Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 47: 490–498

    Article  PubMed  CAS  Google Scholar 

  17. Naranjo CA, Poulos CX, Bremner KE, Lanctot KL (1992) Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther 51: 729–739

    Article  PubMed  CAS  Google Scholar 

  18. Gorelick DA, Paredes A (1992) Effect of fluoxetine on alcohol consumption in male alcoholics. Alcoho Clin Exp Res 16: 261–265

    CAS  Google Scholar 

  19. Naranjo CA, Bremner KE, Lanctot KL (1995) Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 90: 87–99

    PubMed  CAS  Google Scholar 

  20. Kabel DI, Petty F (1996) A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res 20: 780–784

    PubMed  CAS  Google Scholar 

  21. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N (1995) Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 152: 391–397

    PubMed  CAS  Google Scholar 

  22. Buydens-Branchey L, Branchey MH, Noumair D (1989) Age of alcoholism onset. I. Relationship to psychopathology. Arch Gen Psychiatry 46: 225–230

    PubMed  CAS  Google Scholar 

  23. Linnoila M, Virkkunen M (1992) Biologic correlates of suicidal risk and aggressive behavioral traits. J Clin Psychopharmacol 12: 19S–20S

    PubMed  CAS  Google Scholar 

  24. Linnoila M, De Jong J, Virkkunen M (1989) Family history of alcoholism in violent offenders and impulsive fire setters. Arch Gen Psychiatry 46: 613–616

    PubMed  CAS  Google Scholar 

  25. Fils-Aime ML, Eckardt MJ, George DT, Brown GL, Mefford I, Linnoila M (1996) Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics. Arch Gen Psychiatry 53: 211–216

    PubMed  CAS  Google Scholar 

  26. Kranzler HR, Burleson JA, Brown J, Babor TF (1996) Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res 20: 1534–1541

    PubMed  CAS  Google Scholar 

  27. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A (2000) Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 24: 1041–1049

    PubMed  CAS  Google Scholar 

  28. Johnson BA, Cloninger CR, Roache JD, Bordnick PS, Ruiz P (2000) Age of onset as a discriminator between alcoholic subtypes in a treatment-seeking outpatient population. Am J Addict 9: 17–27

    PubMed  CAS  Google Scholar 

  29. Johnson BA, Ait-Daoud N (2000) Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 149: 327–344

    Article  PubMed  CAS  Google Scholar 

  30. Johnson BA (2000) Serotonergic agents and alcoholism treatment: rebirth of the subtype concept—an hypothesis. Alcohol Clin Exp Res 24: 1597–1601

    PubMed  CAS  Google Scholar 

  31. Stoltenberg SF (2003) Serotonergic agents and alcoholism treatment: a simulation. Alcohol Clin Exp Res 27: 1853–1859

    PubMed  CAS  Google Scholar 

  32. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, Thase ME, Black A (1997) Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 54: 700–705

    PubMed  CAS  Google Scholar 

  33. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB (1996) A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 275: 761–767

    Article  PubMed  CAS  Google Scholar 

  34. McGrath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek-Welikson K, Quitkin FM (1996) Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry 53: 232–240

    PubMed  CAS  Google Scholar 

  35. Collins DM, Myers RD (1987) Buspirone attenuates volitional alcohol intake in the chronically drinking monkey. Alcohol 4: 49–56

    Article  PubMed  CAS  Google Scholar 

  36. Privette TH, Hornsby RL, Myers RD (1988) Buspirone alters alcohol drinking induced in rats by tetrahydropapaveroline injected into brain monoaminergic pathways. Alcohol 5: 147–152

    Article  PubMed  CAS  Google Scholar 

  37. Meert TF (1993) Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. Alcohol Alcoholism 28: 157–170

    CAS  Google Scholar 

  38. Wilson AW, Costall B, Neill JC (2000) Manipulation of operant responding for an ethanol-paired conditioned stimulus in the rat by pharmacological alteration of the serotonergic system. J Psychopharmacol 14: 340–346

    PubMed  CAS  Google Scholar 

  39. Rezvani AH, Overstreet DH, Janowsky DS (1990) Genetic serotonin deficiency and alcohol preference in the fawn hooded rats. Alcohol Alcoholism 25: 573–575

    CAS  Google Scholar 

  40. Gongwer MA, Murphy JM, McBride WJ, Lumeng L, Li TK (1989) Regional brain contents of serotonin, dopamine and their metabolites in the selectively bred high-and low-alcohol drinking lines of rats. Alcohol 6: 317–320

    Article  PubMed  CAS  Google Scholar 

  41. McBride WJ, Bodart B, Lumeng L, Li TK (1995) Association between low contents of dopamine and serotonin in the nucleus accumbens and high alcohol preference. Alcohol Clin Exp Res 19: 1420–1422

    PubMed  CAS  Google Scholar 

  42. Korpi ER, Paivarinta P, Abi-Dargham A, Honkanen A, Laruelle M, Tuominen K, Hilakivi LA (1992) Binding of serotonergic ligands to brain membranes of alcohol-preferring AA and alcohol-avoiding ANA rats. Alcohol 9: 369–374

    PubMed  CAS  Google Scholar 

  43. Blier P, Ward NM (2003) Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 53: 193–203

    Article  PubMed  CAS  Google Scholar 

  44. Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A (1992) A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 16: 1007–1013

    PubMed  CAS  Google Scholar 

  45. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, Bohn MJ (1994) Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 51: 720–731

    PubMed  CAS  Google Scholar 

  46. Fawcett J, Kravitz HM, McGuire M, Easton M, Ross J, Pisani V, Fogg LF, Clark D, Whitney M, Kravitz G et al. (2000) Pharmacological treatments for alcoholism: revisiting lithium and considering buspirone. Alcohol Clin Exp Res 24: 666–674

    PubMed  CAS  Google Scholar 

  47. Bruno F (1989) Buspirone in the treatment of alcoholic patients. Psychopathology 22: 49–59

    Article  PubMed  Google Scholar 

  48. Malec TS, Malec EA, Dongier M (1996) Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res 20: 853–858

    PubMed  CAS  Google Scholar 

  49. George DT, Rawlings R, Eckardt MJ, Phillips MJ, Shoaf SE, Linnoila M (1999) Buspirone treatment of alcoholism: age of onset, and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking. Alcohol Clin Exp Res 23: 272–278

    PubMed  CAS  Google Scholar 

  50. Meert TF, Awouters F, Niemegeers CJ, Schellekens KH, Janssen PA (1991) Ritanserin reduces abuse of alcohol, cocaine, and fentanyl in rats. Pharmacopsychiatry 24: 159–163

    Article  PubMed  CAS  Google Scholar 

  51. Myers RD, Lankford M, Bjork A (1992) Selective reduction by the 5-HT antagonist amperozide of alcohol preference induced in rats by systemic cyanamide. Pharmacol Biochem Behav 43: 661–667

    Article  PubMed  CAS  Google Scholar 

  52. Svensson L, Fahlke C, Hard E, Engel JA (1993) Involvement of the serotonergic system in ethanol intake in the rat. Alcohol 10: 219–224

    Article  PubMed  CAS  Google Scholar 

  53. Myers RD, Lankford MF (1996) Suppression of alcohol preference in high alcohol drinking rats: efficacy of amperozide versus naltrexone. Neuropsychopharmacology 14: 139–149

    Article  PubMed  CAS  Google Scholar 

  54. Myers RD, Lankford M (1998) Action of the 5-HT2A antagonist amperozide on alcohol-induced poikilothermia in rats. Pharmacol Biochem Behav 59: 91–95

    Article  PubMed  CAS  Google Scholar 

  55. Biggs TA, Myers RD (1998) Naltrexone and amperozide modify chocolate and saccharin drinking in high alcohol-preferring P rats. Pharmacol Biochem Behav 60: 407–413

    Article  PubMed  CAS  Google Scholar 

  56. Overstreet DH, McArthur RA, Rezvani AH, Post C (1997) Selective inhibition of alcohol intake in diverse alcohol-preferring rat strains by the 5-HT2A antagonists amperozide and FG 5974. Alcohol Clin Exp Res 21: 1448–1454

    PubMed  CAS  Google Scholar 

  57. Lankford MF, Bjork AK, Myers RD (1996) Differential efficacy of serotonergic drugs FG5974, FG5893, and amperozide in reducing alcohol drinking in P rats. Alcohol 13: 399–404

    PubMed  CAS  Google Scholar 

  58. Ugedo L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45–50

    Article  PubMed  CAS  Google Scholar 

  59. Awouters F, Niemegeers CJ, Megens AA, Meert TF, Janssen PA (1988) The pharmacological profile of ritanserin, a very specific central serotonin-S2 antagonist. Drug Dev Res 15: 61–73

    Article  CAS  Google Scholar 

  60. Johnson BA, Jasinski DR, Galloway GP, Kranzler H, Weinreib R, Anton RF, Mason BJ, Bohn MJ, Pettinati HM, Rawson R et al. (1996) Ritanserin in the treatment of alcohol dependence—a multicenter clinical trial. Ritanserin Study Group. Psychopharmacology 128: 206–215

    Article  PubMed  CAS  Google Scholar 

  61. Wiesbeck GA, Weijers HG, Chick J, Naranjo CA, Boening J (1999) Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res 23: 230–235

    PubMed  CAS  Google Scholar 

  62. LeMarquand D, Pihl RO, Benkelfat C (1994) Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biol Psychiatry 36: 326–337

    PubMed  CAS  Google Scholar 

  63. Lovinger DM, White G (1991) Ethanol potentiation of 5-hydroxytryptamine3 receptor-mediated ion current in neuroblastoma cells and isolated adult mammalian neurons. Mol Pharmacol 40: 263–270

    PubMed  CAS  Google Scholar 

  64. Zhou Q, Lovinger DM (1996) Pharmacologic characteristics of potentiation of 5-HT3 receptors by alcohols and diethyl ether in NCB-20 neuroblastoma cells. J Pharmacol Exp Ther 278: 732–740

    PubMed  CAS  Google Scholar 

  65. Lovinger DM, Zhou Q (1994) Alcohols potentiate ion current mediated by recombinant 5-HT3RA receptors expressed in a mammalian cell line. Neuropharmacology 33: 1567–1572

    Article  PubMed  CAS  Google Scholar 

  66. Lovinger DM (1991) Inhibition of 5-HT3 receptor-mediated ion current by divalent metal cations in NCB-20 neuroblastoma cells. J Neurophysiol 66: 1329–1337

    PubMed  CAS  Google Scholar 

  67. Lovinger DM (1991) Ethanol potentiates ion current mediated by 5-HT3 receptors on neuroblastoma cells and isolated neurons. Alcohol Alcoholism Suppl 1: 181–185

    CAS  Google Scholar 

  68. Lovinger DM (1999) 5-HT3 receptors and the neural actions of alcohols: an increasingly exciting topic. Neurochem Int 35: 125–130

    Article  PubMed  CAS  Google Scholar 

  69. Bradbury AJ, Costall B, Domeney AM, Naylor RJ (1985) Laterality of dopamine function and neuroleptic action in the amygdala in the rat. Neuropharmacology 24: 1163–1170

    PubMed  CAS  Google Scholar 

  70. Hagan RM, Jones BJ, Jordan CC, Tyers MB (1990) Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat. Br J Pharmacol 99: 227–232

    PubMed  CAS  Google Scholar 

  71. Eison AS, Iversen SD, Sandberg BE, Watson SP, Hanley MR, Iversen LL (1982) Substance P analog, DiMe-C7: evidence for stability in rat brain and prolonged central actions. Science 215: 188–190

    PubMed  CAS  Google Scholar 

  72. Costall B, Domeney AM, Naylor RJ, Tyers MB (1987) Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92: 881–894

    PubMed  CAS  Google Scholar 

  73. Hodge CW, Samson HH, Lewis RS, Erickson HL (1993) Specific decreases in ethanol-but not water-reinforced responding produced by the 5-HT3 antagonist ICS 205–930. Alcohol 10: 191–196

    Article  PubMed  CAS  Google Scholar 

  74. Fadda F, Garau B, Marchei F, Colombo G, Gessa GL (1991) MDL 72222, a selective 5-HT3 receptor antagonist, suppresses voluntary ethanol consumption in alcohol-preferring rats. Alcohol Alcoholism 26: 107–110

    CAS  Google Scholar 

  75. Rodd-Henricks ZA, McKinzie DL, Li T-K, Crile RS, Murphy JM, McBride WJ (1999) Intracranial self-administration of ethanol into the posterior VTA of Wistar rats is mediated by 5-HT3 receptors [abstract]. Alcohol Clin Exp Res 23(suppl 5): 49A

    Google Scholar 

  76. McBride WJ, Li TK (1998) Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents. Crit Rev Neurobiol 12: 339–369

    PubMed  CAS  Google Scholar 

  77. Tomkins DM, Le AD, Sellers EM (1995) Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. Psychopharmacology 117: 479–485

    Article  PubMed  CAS  Google Scholar 

  78. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083–1152

    Article  PubMed  CAS  Google Scholar 

  79. Beardsley PM, Lopez OT, Gullikson G, Flynn D (1994) Serotonin 5-HT3 antagonists fail to affect ethanol self-administration of rats. Alcohol 11: 389–395

    Article  PubMed  CAS  Google Scholar 

  80. Johnson BA, Campling GM, Griffiths P, Cowen PJ (1993) Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. Psychopharmacology 112: 142–144

    PubMed  CAS  Google Scholar 

  81. Johnson BA, Cowen PJ (1993) Alcohol-induced reinforcement: dopamine and 5-HT3 receptor interactions in animals and humans. Drug Dev Res 30: 153–169

    Article  CAS  Google Scholar 

  82. Doty P, Zacny JP, de Wit H (1994) Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers. Behav Pharmacol 5: 461–469

    PubMed  CAS  Google Scholar 

  83. Swift RM, Davidson D, Whelihan W, Kuznetsov O (1996) Ondansetron alters human alcohol intoxication. Biol Psychiatry 40: 514–521

    Article  PubMed  CAS  Google Scholar 

  84. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB (1994) Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 18: 879–885

    PubMed  CAS  Google Scholar 

  85. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 284: 963–971

    PubMed  CAS  Google Scholar 

  86. Johnson BA, Roache JD, Ait-Daoud N, Zanca NA, Velazquez M (2002) Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology 160: 408–413

    Article  PubMed  CAS  Google Scholar 

  87. Kranzler HR, Pierucci-Lagha A, Feinn R, Hernandez-Avila C (2003) Effects of ondansetron in early-versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res 27: 1150–1155

    PubMed  CAS  Google Scholar 

  88. Bisaga A, Sikora J, Kostowski W (1993) The effect of drugs interacting with serotonergic 5HT3 and 5HT4 receptors on morphine place conditioning. Pol J Pharmacol 45: 513–519

    PubMed  CAS  Google Scholar 

  89. Panocka I, Ciccocioppo R, Polidori C, Pompei P, Massi M (1995) The 5-HT4 receptor antagonist, GR113808, reduces ethanol intake in alcohol-preferring rats. Pharmacol Biochem Behav 52: 255–259

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. South Texas Addiction Research & Technology Center, Departments of Psychiatry and Pharmacology, The University of Texas Health Science Center at San Antonio, 3939 Medical Drive, Suite 100, San Antonio, Texas, 78229-3900, USA

    Bankole A. Johnson

  2. Departments of Psychiatric Medicine and Neuroscience, University of Virginia, P.O. Box 800623, Charlottesville, VA, 22908-0623, USA

    Bankole A. Johnson

Authors
  1. Bankole A. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Psychopharmakologie, Universit ät Heidelberg, J5, Zentralinstitut für Seelische Gesundheit, 68159, Mannheim, Germany

    Rainer Spanagel

  2. Klinik für Abhängiges Verhalten und Suchtmedizin, J5, Zentralinstitut für Seelische Gesundheit, 68159, Mannheim, Germany

    Karl F. Mann

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Johnson, B.A. (2005). Serotonergic compounds: clinical data. In: Spanagel, R., Mann, K.F. (eds) Drugs for Relapse Prevention of Alcoholism. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7305-9_10

Download citation

Publish with us

Policies and ethics

Search

Navigation